NewcelX Ltd. issued an updated corporate presentation in April 2026 emphasizing key progress in its flagship Type 1 Diabetes program, developed in partnership with Eledon Pharmaceuticals. This update follows a $1.35 million private placement and a previously announced $25 million equity line aimed at funding clinical development and general corporate needs. The integration of Kadimastem Ltd. further strengthens NewcelX's R&D pipeline and scientific expertise. While liquidity constraints persist due to development-stage operations, the company remains focused on advancing NCEL-101 clinical milestones and securing future funding.